Endocrine Pharmacology Practice Questions

Q: All are used in the treatment of hot flushes except

Tamoxifen. ***Tamoxifen*** - While Tamoxifen is an **anti-estrogen** used in breast cancer treatment, it can actually **cause or worsen hot flushes** as a side effect due to its estrogen receptor modulating effects in the hypothalamus. - It does not alleviate hot flushes and is therefore not used in their treatment in the general sense. *Gabapentin* - **Gabapentin**, an anticonvulsant, is often used off-label to treat hot flushes, particularly in women who cannot or prefer not to use hormone therapy. - It works by reducing the excitability of thermoregulatory neurons in the hypothalamus. *Clonidine* - **Clonidine**, an alpha-2 adrenergic agonist, can be used to treat hot flushes, especially in menopausal women. - It acts on the central nervous system to reduce the frequency and severity of vasomotor symptoms. *Venlafaxine* - **Venlafaxine**, a serotonin-norepinephrine reuptake inhibitor (SNRI), is a recognized non-hormonal treatment for hot flushes. - It is thought to work by modulating neurotransmitter levels that influence the thermoregulatory center in the brain.

Q: A 60 year old woman is seen at an emergency room after she fractures the neck of her right femur during a minor fall. Radiologic studies demonstrate a generalized loss of bone mass. Exogenous therapy with which of the following hormones would have been most likely to slow or prevent the patient's bone disease?

Estrogen. ***Estrogen*** - **Estrogen deficiency** post-menopause is a primary cause of **osteoporosis** in women due to increased osteoclast activity and bone resorption. - **Exogenous estrogen therapy** could have helped prevent bone loss by inhibiting osteoclast activity and promoting osteoblast function. *Epinephrine* - **Epinephrine** is a catecholamine primarily involved in the **fight-or-flight response**, affecting cardiovascular function and metabolism. - It does not have a direct therapeutic role in preventing **generalized bone mass loss** or treating osteoporosis. *Thyroxine* - **Thyroxine (thyroid hormone)**, especially in excess, can actually accelerate bone turnover and lead to **bone loss** and increased fracture risk. - It is not used to prevent osteoporosis; managing thyroid dysfunction is crucial to bone health. *Cortisol* - **Cortisol** is a glucocorticoid that, when in excess (e.g., in Cushing's syndrome or long-term steroid use), can cause **osteoporosis** by inhibiting bone formation and increasing bone resorption. - Therefore, exogenous cortisol would exacerbate, not prevent, the patient's bone disease.

Q: Most serious adverse effect of Raloxifene is:

Venous thromboembolism. ***Venous thromboembolism*** - **Raloxifene** is a selective estrogen receptor modulator (SERM) that acts as an estrogen agonist in bone but an antagonist in breast and uterine tissues. - It carries a **BLACK BOX WARNING** for increased risk of **venous thromboembolism (VTE)**, including **deep vein thrombosis (DVT)** and **pulmonary embolism (PE)**. - VTE is the **most serious and life-threatening adverse effect**, with a 3-fold increased risk compared to placebo. - **Contraindicated** in patients with active or history of VTE. *Hot flashes* - Very common side effect (occurs in ~25% of patients) due to estrogen antagonist effects. - Bothersome but not life-threatening. - May lead to discontinuation of therapy but does not pose serious health risk. *Leg cramps* - Common side effect of raloxifene, often occurring at night. - Inconvenient but not serious or life-threatening. - Generally manageable with symptomatic treatment. *Stroke* - Raloxifene also increases stroke risk (included in FDA black box warning). - However, in the context of SERM therapy and osteoporosis treatment, **VTE** is the **most emphasized serious adverse effect** in medical education. - Both VTE and stroke are serious, but VTE risk is more consistently highlighted as the primary concern.

Q: True regarding Conivaptan is -

Vasopressin Antagonist. ***Vasopressin Antagonist*** - **Conivaptan** is a non-peptide, dual **V1A and V2 vasopressin receptor antagonist**, blocking the actions of endogenous vasopressin [2], [3]. - By blocking these receptors, it promotes **aquaresis** (excretion of water without significant electrolyte loss), primarily used in cases of **hyponatremia** [1]. *Selective action on V2 receptors* - Conivaptan is a **dual antagonist**, acting on both **V1A and V2 receptors**, not selectively on V2 [2]. **Tolvaptan** is a selective V2 antagonist [1], [2]. - V2 selective antagonists are generally preferred for less off-target effects, but **conivaptan's dual action** can be useful in certain settings. *Administered orally* - Conivaptan is administered **intravenously**, it is **not available as an oral formulation** [3]. - **Tolvaptan**, another vasopressin antagonist, is available for **oral administration**. *Indicated for hypernatremia treatment* - Conivaptan is indicated for the treatment of **euvolemic and hypervolemic hyponatremia**, not hypernatremia [3]. - In hyponatremia, there is an excess of water relative to sodium, and conivaptan helps to **excrete this excess water**.

Q: Wrong statement about SGLT (sodium-glucose linked transporter):

SGLT2 inhibitors worsen heart failure. ***SGLT2 inhibitors worsen heart failure*** - This statement is incorrect because **SGLT2 inhibitors** have been shown to **improve outcomes in heart failure**, reducing hospitalizations and cardiovascular mortality, even in patients without diabetes. - Their beneficial effects in heart failure are attributed to mechanisms such as **osmotic diuresis**, natriuresis, improved cardiac energetics, and reduced preload and afterload. - Landmark trials like **DAPA-HF** and **EMPEROR-Reduced** demonstrated significant benefits in heart failure with reduced ejection fraction (HFrEF). *SGLT2 inhibitors produce weight loss* - **SGLT2 inhibitors** cause **glucosuria** (excretion of glucose in the urine), leading to a loss of calories and subsequent modest weight loss (2-3 kg). - This effect is a common and beneficial side effect, contributing to improved metabolic profiles in patients with type 2 diabetes. *SGLT1 is present in the intestine and kidneys* - **SGLT1** is the primary transporter responsible for glucose absorption in the **small intestine** and is also found in the **kidneys' S3 segment** of the proximal tubule. - In the kidneys, it plays a minor role in glucose reabsorption compared to SGLT2, but it is critical for dietary glucose absorption. *SGLT1 has low capacity and high affinity* - **SGLT1** is characterized by its **high affinity** for glucose (Km ~0.4 mM), allowing it to efficiently reabsorb glucose even at low concentrations. - However, it has a **lower capacity** compared to SGLT2, meaning it reabsorbs a smaller absolute amount of glucose despite its strong binding.

Q: Tolvaptan is used for:-

SIADH. ***SIADH*** - **Tolvaptan** is a **vasopressin V2 receptor antagonist** that promotes water excretion without affecting sodium, making it ideal for treating **euvolemic and hypervolemic hyponatremia** associated with SIADH. - In **syndrome of inappropriate antidiuretic hormone secretion (SIADH)**, there is excessive **ADH** leading to water retention and dilutional hyponatremia; tolvaptan effectively counters this by blocking vasopressin's action. *Von Willebrand disease* - This is a **bleeding disorder** caused by a deficiency or dysfunction of **von Willebrand factor**, treated with **desmopressin** or factor replacement, not tolvaptan. - Tolvaptan has no role in coagulation pathways or the management of bleeding disorders. *Central DI* - **Central diabetes insipidus (DI)** results from reduced **ADH production** by the hypothalamus or posterior pituitary, leading to excessive water loss. - It is treated with **desmopressin** (synthetic ADH) to replace the deficient hormone, which is the opposite effect of tolvaptan. *Catecholamine resistant Shock* - **Catecholamine-resistant shock** is characterized by persistent hypotension despite high doses of **vasopressors**. - Treatment often involves agents like **vasopressin** (not tolvaptan) or corticosteroids to improve vascular tone, as tolvaptan would worsen the hypotension by promoting diuresis.

Q: What is the first-line drug for post-menopausal osteoporosis?

Bisphosphonates. **Bisphosphonates** - **Bisphosphonates** are the **first-line therapy** for postmenopausal osteoporosis due to their proven efficacy in reducing the risk of fragility fractures. - They work by **inhibiting osteoclast activity**, thereby reducing bone resorption and increasing bone mineral density. *Raloxifene* - **Raloxifene** is a **selective estrogen receptor modulator (SERM)** that can be used for osteoporosis prevention and treatment, but it is typically a second-line option, especially in women who cannot tolerate bisphosphonates or have an increased risk of breast cancer. - While it has a positive effect on bone density, its fracture-reduction efficacy is not as broad as bisphosphonates (e.g., it reduces vertebral fractures but has less consistent data on non-vertebral fractures). *Calcitonin* - **Calcitonin** is generally reserved for patients who cannot tolerate other therapies or for short-term use in acute vertebral fractures to help with pain relief. - Its efficacy in reducing fracture risk is **less robust** compared to bisphosphonates, and it is not considered a first-line agent. *Oestrogen* - **Estrogen (hormone replacement therapy)** was once a primary treatment but is now generally not recommended as first-line for osteoporosis due to concerns about increased risks of breast cancer, cardiovascular events, and stroke, particularly in older women. - It is typically reserved for women with significant menopausal symptoms for whom other therapies are contraindicated or ineffective, and for the shortest duration possible.

Q: Agent that acts through tyrosine kinase receptor is

Insulin. ***Insulin*** - **Insulin** binds to its receptor, which is a **tyrosine kinase receptor**, leading to autophosphorylation and the activation of intracellular signaling pathways. - This activation is crucial for glucose uptake and metabolism by various cells in the body. *MSH* - **Melanocyte-stimulating hormone (MSH)** acts primarily through **G protein-coupled receptors**, specifically melanocortin receptors. - These receptors activate adenylyl cyclase, leading to an increase in intracellular cAMP. *TSH* - **Thyroid-stimulating hormone (TSH)** also acts via a **G protein-coupled receptor** on thyroid follicular cells. - Its binding stimulates adenylyl cyclase, increasing cAMP and thus thyroid hormone synthesis and release. *TRH* - **Thyrotropin-releasing hormone (TRH)** binds to **G protein-coupled receptors** on pituitary thyrotrophs. - This interaction activates the phospholipase C pathway, leading to the release of TSH.

Q: Which drug increases bone formation in osteoporosis?

Teriparatide. ***Correct Option: Teriparatide*** - **Teriparatide** is a recombinant form of **parathyroid hormone (PTH)** that, when administered intermittently, stimulates **osteoblast activity** to increase bone formation. - It is an **anabolic agent** specifically designed to build new bone, making it unique among osteoporosis treatments that primarily inhibit bone resorption. - Administered as a **daily subcutaneous injection** for up to 2 years. *Incorrect Option: Calcitonin* - **Calcitonin** is a hormone that inhibits **osteoclast activity**, thereby reducing bone resorption, but does not directly stimulate bone formation. - It may be used for pain relief in acute vertebral fractures but has a minor role in increasing bone density. *Incorrect Option: Risedronate* - **Risedronate** is a **bisphosphonate** that works by inhibiting **osteoclast-mediated bone resorption**, preventing bone breakdown. - It does not directly promote new bone formation; its primary action is to reduce bone turnover. *Incorrect Option: Denosumab* - **Denosumab** is a **monoclonal antibody** that targets and binds to **RANKL**, thereby inhibiting **osteoclast formation, function, and survival**, leading to decreased bone resorption. - Like bisphosphonates, its main mechanism is anti-resorptive, not anabolic.

Q: Drug of choice for post menopausal osteoporosis is

Bisphosphonates. ***Bisphosphonates*** - **Bisphosphonates** are considered the **first-line therapy** for established postmenopausal osteoporosis due to their proven efficacy in reducing the risk of vertebral and non-vertebral fractures. - They work by **inhibiting osteoclast activity**, thereby decreasing bone resorption and increasing bone mineral density. *Estrogen* - While **estrogen therapy** can prevent osteoporosis, it is generally not the first-line treatment due to potential risks like increased risk of **breast cancer**, **stroke**, and **venous thromboembolism**. - It is typically reserved for women with severe menopausal symptoms who also require osteoporosis prevention, and often used at the **lowest effective dose for the shortest duration**. *Thyroxine* - **Thyroxine** is a hormone used primarily to treat **hypothyroidism**, a condition where the thyroid gland doesn't produce enough thyroid hormone. - It is **not indicated for the treatment of osteoporosis** and can even worsen bone loss if given in excessive doses, leading to iatrogenic hyperthyroidism. *Teriparatide* - **Teriparatide** is an **anabolic agent** that stimulates new bone formation, making it a powerful option for severe osteoporosis or those who have failed other therapies. - However, it is an injectable medication with a **limited treatment duration** (typically 2 years) and is generally reserved for patients with a **high fracture risk** rather than being the initial drug of choice for all postmenopausal osteoporosis.

Question 1

All are used in the treatment of hot flushes except

Accepted Answer

Tamoxifen

Answer

Gabapentin

Answer

Clonidine

Answer

Venlafaxine

Question 2

A 60 year old woman is seen at an emergency room after she fractures the neck of her right femur during a minor fall. Radiologic studies demonstrate a generalized loss of bone mass. Exogenous therapy with which of the following hormones would have been most likely to slow or prevent the patient's bone disease?

Accepted Answer

Estrogen

Answer

Epinephrine

Answer

Thyroxine

Answer

Cortisol

Question 3

Most serious adverse effect of Raloxifene is:

Accepted Answer

Venous thromboembolism

Answer

Hot flashes

Answer

Leg cramps

Answer

Stroke

Question 4

True regarding Conivaptan is -

Accepted Answer

Vasopressin Antagonist

Answer

Selective action on V2 receptors

Answer

Administered orally

Answer

Indicated for hypernatremia treatment

Question 5

Wrong statement about SGLT (sodium-glucose linked transporter):

Accepted Answer

SGLT2 inhibitors worsen heart failure

Answer

SGLT2 inhibitors produce weight loss

Answer

SGLT1 is present in the intestine and kidneys

Answer

SGLT1 has low capacity and high affinity

Question 6

Tolvaptan is used for:-

Accepted Answer

SIADH

Answer

Von Willebrand disease

Answer

Central DI

Answer

Catecholamine resistant Shock

Question 7

What is the first-line drug for post-menopausal osteoporosis?

Accepted Answer

Bisphosphonates

Answer

Raloxifene

Answer

Calcitonin

Answer

Oestrogen

Question 8

Agent that acts through tyrosine kinase receptor is

Accepted Answer

Insulin

Answer

MSH

Answer

TSH

Answer

TRH

Question 9

Which drug increases bone formation in osteoporosis?

Accepted Answer

Teriparatide

Answer

Calcitonin

Answer

Risedronate

Answer

Denosumab

Question 10

Drug of choice for post menopausal osteoporosis is

Accepted Answer

Bisphosphonates

Answer

Estrogen

Answer

Thyroxine

Answer

Teriparatide

Endocrine Pharmacology — MCQs

Endocrine Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?